Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ludovica F S Grasso

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Current Opinion in Endocrinology, Diabetes, and Obesity|May 26, 2012
Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate?Ludovica F S Grasso, Rosario Pivonello, Annamaria Colao
Expert Opinion on Investigational Drugs|June 5, 2013
Investigational therapies for acromegalyLudovica F S Grasso, Rosario Pivonello, Annamaria Colao
Expert Opinion on Pharmacotherapy|March 26, 2011
Therapy of aggressive pituitary tumorsAnnamaria Colao, Ludovica F S Grasso, Rosario Pivonello, et al.
Heart Failure Clinics|May 14, 2019
Acromegaly and Heart FailureAnnamaria Colao, Ludovica F S Grasso, Carolina Di Somma, et al.
Expert Opinion on Drug Safety|July 18, 2015
Adverse events associated with somatostatin analogs in acromegalyLudovica F S Grasso, Renata S Auriemma, Rosario Pivonello, et al.
Expert Review of Endocrinology & Metabolism|July 31, 2018
Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegalyLudovica F S Grasso, Renata S Auriemma, Rosario Pivonello, et al.
Expert Opinion on Drug Safety|February 9, 2016
The safety of treatments for prolactinomasRenata S Auriemma, Ludovica F S Grasso, Rosario Pivonello, et al.
Reviews in Endocrine & Metabolic Disorders|September 16, 2008
Medical therapy of pituitary adenomas: effects on tumor shrinkageAnnamaria Colao, Rosario Pivonello, Carolina Di Somma, et al.
Nature Reviews. Disease Primers|March 23, 2019
AcromegalyAnnamaria Colao, Ludovica F S Grasso, Andrea Giustina, et al.
The Journal of Clinical Endocrinology and Metabolism|July 3, 2008
Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 monthsAnnamaria Colao, Rosario Pivonello, Renata S Auriemma, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Current Opinion in Endocrinology, Diabetes, and Obesity|May 26, 2012
Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate?Ludovica F S Grasso, Rosario Pivonello, Annamaria Colao
Expert Opinion on Investigational Drugs|June 5, 2013
Investigational therapies for acromegalyLudovica F S Grasso, Rosario Pivonello, Annamaria Colao
Expert Opinion on Pharmacotherapy|March 26, 2011
Therapy of aggressive pituitary tumorsAnnamaria Colao, Ludovica F S Grasso, Rosario Pivonello, et al.
Heart Failure Clinics|May 14, 2019
Acromegaly and Heart FailureAnnamaria Colao, Ludovica F S Grasso, Carolina Di Somma, et al.
Expert Opinion on Drug Safety|July 18, 2015
Adverse events associated with somatostatin analogs in acromegalyLudovica F S Grasso, Renata S Auriemma, Rosario Pivonello, et al.
Expert Review of Endocrinology & Metabolism|July 31, 2018
Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegalyLudovica F S Grasso, Renata S Auriemma, Rosario Pivonello, et al.
Expert Opinion on Drug Safety|February 9, 2016
The safety of treatments for prolactinomasRenata S Auriemma, Ludovica F S Grasso, Rosario Pivonello, et al.
Reviews in Endocrine & Metabolic Disorders|September 16, 2008
Medical therapy of pituitary adenomas: effects on tumor shrinkageAnnamaria Colao, Rosario Pivonello, Carolina Di Somma, et al.
Nature Reviews. Disease Primers|March 23, 2019
AcromegalyAnnamaria Colao, Ludovica F S Grasso, Andrea Giustina, et al.
The Journal of Clinical Endocrinology and Metabolism|July 3, 2008
Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 monthsAnnamaria Colao, Rosario Pivonello, Renata S Auriemma, et al.
Pageof 3